Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
They’re rare, they’re confounding, and R&D for therapies to address them is painfully underfunded. Rare diseases affect approximately 30 million people in the U.S.—half of them children—but investment in this space is a fraction of what it is for more …